“Research has shown that Medicaid expansion can increase cancer screening prevalence, early-stage diagnosis, short-term ...

Beyond this study population, there are ongoing randomized trials evaluating NBTXR3 for definitive treatment of HNSCC, including a trial for cisplatin-ineligible patients, as well as a planned study ...

Orphan drug designation provides benefits such as tax credits, PDUFA fee waivers, and 7 years of market exclusivity upon ...

mRNA-4359 combined with pembrolizumab achieved a 24% ORR and 67% efficacy in PD-L1 positive melanoma patients. The study ...

Tagraxofusp demonstrated a manageable safety profile but limited efficacy in CMML patients, with stable disease as the best ...

Acalabrutinib (Calquence) yielded high efficacy and a manageable safety profile for the treatment of chronic lymphocytic ...

SpaceOAR Hydrogel is a polyethylene glycol–based hydrogel designed to create space between the prostate and rectum to reduce ...

Tucatinib enhances progression-free survival (PFS) in HER2+ metastatic breast cancer, showcasing promising results in a ...

T-cell engagers, especially BiTEs, show promise in treating solid tumors by targeting tumor-associated antigens and redirecting T-cell activity. Tarlatamab, targeting DLL3 in SCLC, demonstrated ...

With the 2025 European Society of Medical Oncology (ESMO) Congress kicking off on Friday, October 17, in Berlin, Germany, Targeted Oncology is bringing you background on the most exciting abstracts ...

The primary end point of the dose-expansion portion was safety of NBTXR3 at the recommended dosage, 1 which was established ...

FDA fast track designation for NG-350A aims to expedite its development for mismatch repair-proficient locally advanced ...